Nanomedicine uses engineered particles roughly 1 to 100 nanometers in size to diagnose, treat, or prevent disease. That scale is thousands of times smaller than the width of a human hair, small enough to interact with individual cells and even slip past biological barriers that block conventional drugs. The field produced some of its most visible results during the COVID-19 pandemic, when lipid nanoparticles carried mRNA into billions of arms worldwide, but the applications stretch far beyond vaccines into cancer therapy, gene editing, brain-targeted delivery, and cardiovascular disease. What makes nanomedicine compelling is not the novelty of tiny particles but the practical problems they solve, and the stubborn challenges that remain.
How Nanoparticles Find Their Targets
One of the oldest and most studied applications of nanomedicine is cancer treatment, and the central question there is straightforward: how do you get a drug into a tumor without poisoning everything else? Two broad strategies exist. The first is passive targeting, which exploits a quirk of tumor biology. Tumors grow fast and build sloppy blood vessels with gaps in the vessel walls. Nanoparticles in the right size range can leak through those gaps and accumulate in tumor tissue more than in healthy tissue. This phenomenon, known as the enhanced permeability and retention (EPR) effect, has been the workhorse rationale behind decades of cancer nanomedicine research.1PubMed. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
The second strategy is active targeting. Here, researchers attach molecules to the nanoparticle surface that recognize and bind to receptors found in unusually high numbers on cancer cells or on the blood vessels feeding the tumor. Think of it as sticking a postal address on the particle. The EPR effect gets the nanoparticle into the neighborhood; active targeting helps it knock on the right door.2PubMed. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery In practice, most experimental nanomedicines combine both approaches, though the clinical track record of active targeting has been slower to materialize than early enthusiasm suggested.
Lipid Nanoparticles and the mRNA Vaccine Breakthrough
Before COVID-19, lipid nanoparticles (LNPs) were a niche topic in pharmaceutical science. After 2020, they became household technology. LNPs are tiny fat-based shells built from four components: an ionizable lipid that helps the particle get inside cells, a helper lipid, cholesterol for structural stability, and a lipid linked to polyethylene glycol (PEG) that helps the particle evade the immune system long enough to reach its target.3PubMed Central. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines These particles protect fragile mRNA from degradation in the bloodstream and ferry it into cells, where the mRNA instructs the cell to produce a protein, in the vaccine case, the SARS-CoV-2 spike protein that trains the immune system.
The evolution from early liposomes to modern LNPs spans decades. Liposomes, essentially hollow fat bubbles, were among the first nanomedicine platforms and led to several approved drugs. Later generations, including solid lipid nanoparticles and nanostructured lipid carriers, added physical stability and more complex internal architectures.4PubMed. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement The COVID-era LNPs were the culmination of that long development arc rather than a sudden invention.
Researchers are now pushing LNP design further. A 2024 study showed that changing the internal structure of LNPs, specifically the ratio and arrangement of their lipid components, dramatically affects how the particles deliver mRNA. Particles with an emulsion-like internal structure stayed at the injection site and produced antigen locally. The immune response from those particles was faster at two weeks and stronger at eight weeks compared with particles that had a more conventional internal structure.5PubMed. Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity Findings like these suggest there is still considerable room to optimize LNPs for next-generation vaccines and other mRNA therapies.
Gold and Iron Oxide Nanoparticles
Not all nanomedicine is made from fats and polymers. Inorganic nanoparticles, particularly gold and iron oxide, bring capabilities that organic materials cannot easily match.
Gold nanoparticles absorb light at specific wavelengths and convert it to heat, a property that makes them useful for both imaging and therapy. By changing the shape or size of gold nanoparticles, researchers can tune which wavelengths of light they respond to, including near-infrared light, which penetrates tissue more deeply than visible light.6PubMed Central. Gold Nanoparticles for Photothermal Cancer Therapy In animal studies, gold nanostars injected into tumors and then illuminated with a near-infrared laser heated the tumor enough to destroy it, while surrounding tissue without the particles was unaffected.7PubMed Central. A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy The same particles also served as contrast agents for CT scans and other imaging methods, allowing doctors to both locate the tumor and treat it with a single platform.8PubMed. Gold nanoparticle-mediated photothermal therapy: Expanding the frontiers of cancer treatment and theragnostics
Iron oxide nanoparticles play a complementary role. They respond to magnetic fields, which makes them useful as MRI contrast agents, as carriers that can be steered magnetically toward a target, and as agents for magnetic hyperthermia, where an alternating magnetic field heats the particles to damage tumor cells.9PubMed Central. Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review Performance depends heavily on crystal quality. Two batches of iron oxide nanocubes with almost identical size and shape can behave very differently if one has defects in its crystal structure that disrupt how its magnetic moment aligns.10Chemistry of Materials. Correlating Magnetic Hyperthermia and Magnetic Resonance Imaging Contrast Performance of Cubic Iron Oxide Nanoparticles with Crystal Structural Integrity That sensitivity to crystal-level details is one reason manufacturing reproducibility remains a challenge for inorganic nanomedicines.
The Protein Corona Problem
The moment a nanoparticle enters the bloodstream, proteins rush to coat its surface, forming what researchers call a protein corona. This layer fundamentally changes the particle’s identity as far as the body is concerned. The corona determines whether the immune system attacks the particle, how quickly it gets cleared from circulation, and whether it reaches its intended target.11PubMed. Engineering the protein corona: Strategies, effects, and future directions in nanoparticle therapeutics A nanoparticle designed to dodge immune cells in the lab can behave completely differently once coated in blood proteins.
The corona’s composition depends on both the biological environment and the particle’s physical properties. It can either stimulate or dampen the immune response depending on which proteins adsorb.12PubMed Central. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity Researchers have begun using machine learning to predict which proteins will stick to a given nanoparticle and how that corona will affect cellular behavior. One model achieved good accuracy in predicting the functional protein composition of the corona, including immune proteins and apolipoproteins, and was then able to predict downstream cellular responses like uptake by immune cells.13PubMed Central. Machine learning predicts the functional composition of the protein corona and the cellular recognition of nanoparticles That kind of predictive power could speed up nanoparticle design considerably, since testing every possible surface chemistry in the lab is impractical.
Getting Past the Blood-Brain Barrier
The blood-brain barrier is one of the most effective gatekeepers in the human body, and one of the biggest obstacles in neurology. It keeps most drugs out of the brain, which is why conditions like brain tumors, Alzheimer’s disease, and Parkinson’s disease remain so difficult to treat. Nanomedicine offers a strategy: disguise the particle as something the barrier already lets through.
Transferrin, a protein the brain needs for iron transport, has receptors on the cells lining the blood-brain barrier. Researchers have coated gold nanoparticles with transferrin and injected them into mice, observing that the particles crossed into the brain tissue. The trick was getting the amount of transferrin right. Particles loaded with too much transferrin stuck to the blood-side surface of the barrier and never detached on the brain side. Particles with a moderate coating interacted with the receptor just enough to cross, then released on the other side.14PubMed Central. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor A similar approach used lactoferrin, another protein with receptors on brain endothelial cells, attached to PEG-coated iron oxide nanoparticles. These particles showed enhanced ability to cross the barrier compared with undecorated particles.15PubMed. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier
These results remain mostly preclinical. Translating blood-brain barrier penetration from mice to humans is notoriously difficult, and the quantities of drug delivered to the brain so far are modest. But the principle, hijacking the brain’s own transport systems, is one of the more promising leads for neurological drug delivery.
Delivering Gene-Editing Tools
CRISPR gene editing needs a delivery vehicle. The editing machinery, a protein paired with a guide RNA, is large, fragile, and does not cross cell membranes on its own. Viral vectors can do the job, but they carry risks: they can integrate into the genome in unwanted places, and the immune system often recognizes them and mounts a response that limits repeat dosing. Nanoparticles sidestep both issues. Lipid and polymer-based nanocarriers have shown strong potential for shuttling CRISPR components into cells without the drawbacks of viral delivery.16PubMed Central. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
One research group engineered modified lipid nanoparticles that delivered CRISPR ribonucleoproteins, the protein-RNA complex itself rather than a DNA blueprint, into mice. By adjusting the lipid composition, they achieved tissue-specific editing in muscle, brain, liver, and lungs from a single intravenous injection. In the lungs, they simultaneously edited six genes.17Nature Communications. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing Delivering the protein directly rather than encoding it in DNA is attractive because the editing machinery is active only briefly, reducing the chance of off-target cuts that accumulate when the protein is expressed for an extended period.18PubMed Central. Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing
Stimulus-Responsive and Theranostic Designs
A growing class of “smart” nanoparticles is designed to stay inert during circulation and activate only when they encounter the right biological signal. Tumors, for example, tend to be more acidic than healthy tissue, have elevated levels of certain enzymes, and contain regions of low oxygen. Stimulus-responsive nanoparticles exploit those differences, releasing their drug payload or changing their surface properties only in the tumor microenvironment.19PubMed Central. Stimuli-responsive nanoparticles for targeting the tumor microenvironment This approach reduces off-target drug exposure compared with particles that release their contents indiscriminately.
Closely related is the concept of theranostics, platforms that combine therapy and diagnostic imaging in one particle. Rather than using one injection to image a tumor and another to treat it, a theranostic nanoparticle does both. A single platform might carry a drug, a fluorescent label for optical imaging, and a contrast agent for MRI, enabling clinicians to watch the particle reach the tumor, confirm it arrived, and then trigger treatment.20PubMed Central. MRI-traceable theranostic nanoparticles for targeted cancer treatment The gold nanostar system described earlier is one example: the same particle provided CT imaging, optical imaging, and photothermal therapy in mice.21PubMed Central. A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy These multifunctional platforms are expected to contribute to more personalized treatment decisions, where imaging feedback guides whether to proceed with therapy, adjust the dose, or switch strategies.22PubMed Central. Imaging and drug delivery using theranostic nanoparticles
Beyond Cancer
Cancer dominates nanomedicine research, but the technology is being applied to other diseases. Cardiovascular disease is a major area. Atherosclerotic plaques, the fatty buildups inside artery walls that cause heart attacks and strokes, involve specific cell types and molecular processes that nanoparticles can target. Nanoparticles have been engineered to home in on the macrophages, foam cells, and endothelial cells involved in plaque formation, offering possibilities for both imaging plaques and delivering anti-inflammatory or anti-thrombotic drugs directly to them.23PubMed Central. Detection and treatment of atherosclerosis using nanoparticles Conventional drugs for atherosclerosis act systemically, which limits their doses and effectiveness. Targeted nanoparticles could allow higher local drug concentrations with fewer side effects.24PubMed Central. Nanotechnology for Targeted Therapy of Atherosclerosis
Antibiotic-resistant infections are another frontier. Bacterial biofilms, the slimy communities bacteria form on surfaces like implants and wounds, are notoriously resistant to conventional antibiotics because the biofilm acts as a physical and chemical shield. Various types of nanoparticles, including metal and metal oxide particles, liposomes, and polymeric nanoparticles, are being explored as delivery platforms that can penetrate biofilms and deliver antimicrobial agents where they are needed.25PubMed Central. Nanotechnology in combating biofilm: A smart and promising therapeutic strategy Some metallic nanoparticles, particularly silver, have intrinsic antimicrobial properties and can damage bacteria through multiple mechanisms simultaneously, making it harder for bacteria to develop resistance.26ACS Nano Medicine. Engineered Nanoparticles for Combating Drug-Resistant Bacteria and Bacterial Biofilms
Oral Delivery of Fragile Drugs
Swallowing a pill is the easiest way to take a medication, but many of the most promising biological drugs, especially peptides like insulin, are destroyed by stomach acid and digestive enzymes before they can be absorbed. Nanomedicine is working to change that. Polymer-based and lipid-based nanocarriers can shield peptides from the harsh gastrointestinal environment and promote absorption through the intestinal lining.27Journal of Drug Delivery Science and Technology. Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers
A recent study illustrates the engineering involved. Researchers loaded insulin into mesoporous silica nanoparticles and formulated them into tablets that respond to pH changes. In acidic conditions mimicking the stomach, only about 13% of the insulin leaked out over two hours. In conditions mimicking the intestine, up to 98% was released in a controlled manner. Surface modifications increased insulin solubility roughly 2.5-fold, and the particles triggered a temporary loosening of the junctions between intestinal cells, doubling the amount of insulin that crossed the intestinal wall compared with free insulin.28PubMed Central. Mesoporous Silica Nanoparticles-Based Formulations for Enhanced Oral Delivery of Peptide Drugs: A Case Study on Insulin An oral insulin pill that actually works at a clinically meaningful level would be transformative for diabetes management, but the gap between promising lab data and a product on pharmacy shelves remains wide.
Safety and the Immune System
Because nanoparticles are sized similarly to viruses, the immune system sometimes treats them the same way. One well-documented concern is complement activation, where nanoparticles trigger a cascade of immune proteins that can cause acute inflammatory reactions. In severe cases, this can lead to a condition called complement activation-related pseudoallergy (CARPA), which has been observed with some clinical nanomedicines and can range from mild flushing to serious anaphylaxis-like reactions.29PubMed. A shift of paradigm: From avoiding nanoparticular complement activation in the field of nanomedicines to its exploitation in the context of vaccine development PEGylation, coating particles with polyethylene glycol to make them “stealthier,” reduces but does not eliminate this problem. Interestingly, the same complement activation that is a liability for drug delivery nanoparticles may actually be an asset for vaccines, where you want an immune response. Researchers have begun deliberately exploiting this property to boost vaccine effectiveness.30PubMed Central. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine
Size also determines how the body eliminates nanoparticles. Particles smaller than about 6 nanometers in diameter can pass through the kidneys and be excreted in urine. Particles larger than about 8 nanometers generally cannot, and those in the 6-to-8 nanometer range are filtered depending on both their size and their surface charge.31PubMed Central. Clearance Properties of Nano-sized Particles and Molecules as Imaging Agents: Considerations and Caveats Larger nanoparticles are instead taken up by the liver and spleen. Designing nanoparticles that do their job and then leave the body cleanly, without accumulating in organs, remains an active area of work.32PubMed Central. Clearance Pathways and Tumor Targeting of Imaging Nanoparticles
Why So Few Have Reached Patients
Given the volume of nanomedicine research, it is reasonable to wonder why relatively few nano-formulated drugs are on the market. The gap between laboratory promise and clinical reality is one of the field’s defining tensions. Challenges cluster in several areas: translating results from animal models that do not perfectly reflect human biology, scaling up manufacturing while keeping particle properties consistent, navigating regulatory frameworks that were not designed with nanoparticles in mind, and demonstrating meaningful clinical benefit over cheaper, simpler alternatives.33PubMed. Clinical translation of nanomedicines: Challenges, opportunities, and keys
Regulatory ambiguity is a persistent issue. Nanomedicines straddle traditional categories: they are not purely drugs, not purely devices, and not purely biological products. Without clear, consolidated guidance on how to characterize, test, and approve them, developers face uncertainty that slows investment and clinical trial design.34PubMed Central. Current hurdles to the translation of nanomedicines from bench to the clinic
Manufacturing is making progress. Microfluidic synthesis, where nanoparticles are assembled in precisely controlled tiny channels, offers better reproducibility and easier scaling than traditional batch mixing. The same microfluidic setup can also be used for high-throughput screening of different formulations, accelerating the design-to-production pipeline.35PubMed. A toolbox to optimize and scale up microfluidic production of lipid-based nanoparticles The COVID-19 vaccine rollout demonstrated that LNP manufacturing can scale to billions of doses, which has shifted perceptions about what is industrially feasible. Whether that manufacturing confidence extends to more complex nanoparticle architectures, multi-component theranostic platforms, for instance, is an open question.
Polymer-Based Sustained Release
Alongside lipid and inorganic nanoparticles, polymer-based carriers form a major branch of nanomedicine. Materials like PLGA (a biodegradable polymer already used in surgical sutures) can be formed into nanoparticles that release a drug slowly over days or weeks. In one study, PLGA nanoparticles showed an initial burst of drug release in the first two days, followed by sustained release over the subsequent four weeks.36PLOS ONE. Externally Controlled Triggered-Release of Drug from PLGA Micro and Nanoparticles Combining PLGA with chitosan, a natural polymer derived from crustacean shells, has been explored as a way to improve the delivery of negatively charged drugs like low molecular weight heparin, a blood thinner.37PubMed Central. Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin
The appeal of sustained-release polymer nanoparticles is practical: fewer doses, more consistent drug levels, and potentially fewer side effects from peaks and troughs. For drugs that need to be present at a steady level over long periods, such as anticoagulants after surgery or hormonal therapies, this kind of controlled release is a natural fit. The challenge is tuning the release rate precisely and ensuring the polymer breakdown products are harmless, which PLGA’s long regulatory track record helps address.